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acting beta agonists. Several systematic reviews have evaluated the use of anticholinergics with mixed results.
Tiotropium bromide became available in the United States in 2004, yet there have been few studies utilizing
this long acting anticholinergic for the treatment of asthma patients.
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with the use of tiotropium in addition to an ICS. GRADE was used to rate the quality of evidence.
Method: An exhaustive search of the available literature using Medline, Pubmed, Web of Science, Cochrane
Systematic Reviews and CINHAL. The keywords used included “tiotropium”, “asthma” and “adults”
individually and in combination.
Results: Four articles were found to be relevant to the topic of this paper. Two randomized clinical trials
showed statistically improved lung function with the addition of tiotropium to an ICS. One observational
study showed that 33% of patients demonstrated a response of ≥ 15% improvement in FEV1 with the addition
of tiotropium. A case report also demonstrated improvements in PEF and a decrease in oral steroid use in a
chronic asthma patient.
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lung function for adult patients with chronic asthma. This conclusion is based on a moderate grade of
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ABSTRACT 
 
Background:  Asthma is a chronic respiratory disease effecting 24.6 million 
children and adults in the United States.  Current treatment guidelines 
recommend the use of inhaled corticosteroids and both short and long acting 
beta agonists.  Several systematic reviews have evaluated the use of 
anticholinergics with mixed results.  Tiotropium bromide became available in the 
United States in 2004, yet there have been few studies utilizing this long acting 
anticholinergic for the treatment of asthma patients. 
 
Purpose:  This paper evaluates the current literature on the improvements in 
pulmonary function in asthmatics with the use of tiotropium in addition to an ICS.  
GRADE was used to rate the quality of evidence. 
 
Method: An exhaustive search of the available literature using Medline, Pubmed, 
Web of Science, Cochrane Systematic Reviews and CINHAL.  The keywords 
used included “tiotropium”, “asthma” and “adults” individually and in combination. 
 
Results:  Four articles were found to be relevant to the topic of this paper.  Two 
randomized clinical trials showed statistically improved lung function with the 
addition of tiotropium to an ICS.  One observational study showed that 33% of 
patients demonstrated a response of • 15% improvement in FEV1 with the 
addition of tiotropium.  A case report also demonstrated improvements in PEF 
and a decrease in oral steroid use in a chronic asthma patient. 
 
Conclusion:  Tiotropium bromide in conjunction with an ICS provides statistically 
significant improvement in lung function for adult patients with chronic asthma.  
This conclusion is based on a moderate grade of evidence using the GRADE 
analysis. 
 
Keywords: Tiotropium, inhaled corticosteroid, asthma, adult asthma. 
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INTRODUCTION 
Background 
Asthma is a chronic respiratory disease effecting both children and adults 
with significant morbidity and mortality.  It contributes to significantly personal, 
social and economic burdens.  Asthma is characterized by recurring bronchial 
inflammation, airway obstruction and airway hyper-responsiveness.  According to 
the Center for Disease Control (CDC), as of 2009, 24.6 million children and 
adults in the United States (8.2% of the population) currently have asthma.  In 
2008 there were 10.5 million missed school days and 14.2 million missed work-
days due to asthma.  For 2007 1.75 million asthmatics required emergency 
department visits and 456,000 required hospitalizations for exacerbations of their 
condition.  Health statistics from 2007 determined that there were 3,447 deaths 
due to asthma in that year.  The prevalence of asthma has increased by an 
average 1.2% annually between 2001 and 2009. (Akinbami, Moorman and Liu, 
2011).  
Current treatment guidelines published in 2007 by the National Asthma 
Education and Prevention Program (National Heart, Lung and Blood Intstitute, 
2007) were developed to provide a best practices approach for clinicians to 
diagnose and treat patients with asthma.  The guidelines provide a step-wise 
approach based on asthma severity to monitor and control patient symptoms.  
Patients with intermittent asthma are managed with short acting beta agonists 
(SABA), such as albuterol, on an as needed basis.  As the severity increases the 
preferred treatment is a low dose inhaled corticosteroid (ICS).  If the patient has 
moderate to severe asthma the recommendation is to add a long acting beta 
agonist (LABA) to the ICS or to increase the dose of the ICS.  However, the U.S. 
Food and Drug Administration (2010) now requires manufacturers to include a 
warning for LABAs due to potential increases in asthma exacerbations and 
deaths in asthma patients.  This possible safety issue has lead researchers to 
study the use of long-acting anticholinergics such as tiotropium bromide in the 
treatment of moderate to severe asthmatics. (Peters, et al, 2010).  Tiotropium is 
currently indicated for the treatment of Chronic Obstructive Pulmonary Disease 
(COPD), however it is not indicated for the treatment of asthma.  The efficacy of 
tiotropium in COPD has been demonstrated in multiple randomized clinical trials 
including a long-term use trial by Tashkin, Celli, Kesten, Lystig and Decremer 
(2010).  Based on recently published studies, tiotropium may prove to be an 
effective treatment option in conjunction with an ICS. 
Previous systematic reviews have evaluated the use of anticholinergics in 
the treatment of asthma with mixed results.   A systematic review by Westby, 
Benson and Gibson (2004) did not find enough adequate data at the time to 
determine the specific role that long-acting anticholinergics have in the treatment 
of chronic asthma.  In the review by Flynn, Glynn and Kennedy (2009), the 
authors concluded that there was not enough current data to support the use of 
anticholinergics in chronic asthma.  The review by Donahue (2004) found that 
anticholinergic agents provide more benefit to patients with COPD than patients 
with asthma.  However, he concluded that some asthmatics, especially the 
elderly patients with a history of smoking or with concurrent beta-blocker use 
might benefit from the addition of an anticholinergic. 
Most studies of anticholinergic use in asthma patients in the past have 
evaluated the effects of ipratropium on the improvement of lung function in both 
acute and chronic asthma.  Ipratropium is a short acting anticholinergic that 
requires dosing every 6 hours. In 2004, tiotropium became available in the United 
states as a once-daily anticholinergic agent for the treatment of patients with 
COPD.  Recently, there has been interest to continue to evaluate the use of 
anticholinergics in asthma patients with the availability of the longer acting 
tiotropium. 
 
Purpose of the Study 
The purpose of this paper is to perform a systematic review of the literature on 
the use of tiotropium bromide as an adjunct to inhaled corticosteroids for patients 
suffering from moderate to severe asthma using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) tool 
developed by the GRADE Working Group. 
METHODS 
 
An extensive literature search was performed using Medline, Pubmed, 
Web of Science, Cochrane Systematic Reviews and CINHAL. These databases 
were accessed through the Pacific University Library system. The keywords 
searched included “tiotropium”, “asthma” and “adults” individually and in 
combination. The search was limited to human subjects and the English 
language.  The initial results included 37 articles. Articles older than January 
2000 and duplicates were excluded. Articles with COPD as the main topic were 
also excluded.  Four articles were chosen for this review based on their 
relevance to the topic. 
RESULTS  
The first study reviewed was conducted by Peters et al. (2010) and was 
funded by the National Heart, Blood and Lung Institute who published their 
results in an article entitled Tiotropium Bromide as an Alternative to Increased 
Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of 
Inhaled Corticosteroid (TALC) Study.   The study was a randomized, double-
blind, triple crossover study that compared the outcomes of the addition of 
tiotropium, salmeterol or increased dose of beclamethasone (Qvar) in patients 
that were not controlled with a lower dose of ICS.  Patients were enrolled in the 
study if they were over the age of 18, had a history of asthma, a forced expiratory 
volume greater than 40%, and less than a 10 pack year history of smoking.   
Each participant was subjected to a common four week run-in period that 
included treatment with 80 µg beclamethasone meter dosed inhaler (Qvar) twice 
daily.  Patients that at the end of the four week run-in period had  less than 70% 
predicted FEV1 and no contraindication for tiotropium were then randomized into 
one of three treatment arms.  One arm consisted of 160 µg beclamethasone 
twice daily and placebo for tiotropium and salmeterol.  The second arm was 
treated with 80 µg beclamethsone twice daily and 18 µg tiotropium bromide once 
daily and placebo in place of salmeterol.  The third arm was treated with 80 µg of 
beclamethasone twice daily, salmeterol xinafoate 50 µg inhaler (Serevent) twice 
daily and a tiotropium placebo.  Each arm was treated for 14 weeks and then 
washed-out for two weeks on just 80 µg beclamethasone inhaler twice daily.  
They were then crossed over to another treatment arm for an additional 14 
weeks. This was followed by an additional two week wash-out period and 
another crossover in treatment arms. The primary outcome in the study was the 
difference in the morning peak expiratory flow (PEF) compared to baseline.  
Secondary outcomes included; evening PEF, albuterol rescue inhaler use, mean 
daily symptom score, proportion of asthma-control days, prebronchodilator FEV1, 
Asthma Symptom Utility Index Score, Asthma-Control Questionnaire score, 
Asthma Quality-Of-Life Questionnaire score and forced expiratory volume in one 
second (FEV1) after four puffs of albuterol. The mean difference in change from 
baseline of the morning PEF for the tiotropium versus double-dose 
beclamethasone was 25.8L per minute, 95% confidence interval (14.4 – 37.1), p-
value < 0.001. The tiotropium versus double-dose beclamethasone analysis had 
a mean difference change from baseline for the evening PEF of 35.3L per 
minute, 95% CI (24.6 – 46.0), p-value < 0.001.  The tiotropium versus salmeterol 
analysis had a mean difference change from baseline for morning and evening 
PEF of 6.4L per minute, 95% CI (-4.8 – 17.5), p-value 0.26 and 10.6L per minute, 
95% CI (-0.1 –  21.3), p-value 0.05, respectively.  The salmeterol versus double-
dose beclamethasone analysis had morning and evening PEF differences of 
19.4L per minute, 95% CI (9.4 - 29.4), p-value <0.001 and 24.7L per minute, 95% 
CI (15.2 – 34.3), p-value <0.001, respectively.  The authors determined that 
tiotropium in addition to an ICS provided statistically better PEF when compared 
to twice the dose of ICS.  They also reported that the addition of tiotropium to an 
ICS was not inferior to the use of salmeterol and an ICS.   
The next study reviewed was conducted by Park et al. (2009) and 
evaluated the response of severe asthmatics to the addition of tiotropium to high-
dose ICS and an inhaled LABA.  They enrolled 160 patients diagnosed with 
severe persistent asthma determined by lung function testing and medication 
usage records.  The patients also had to have • 10 pack year history of smoking, 
a change in FEV1 of less than 5% over eight consecutive weeks prior to study 
enrollment, and no abnormalities detected on chest radiograph.  The patients in 
this study were being treated with a high-dose corticosteroid (equivalent dose to 
800-1600 µg of budesonide inhaler) and a LABA.  Tiotropium bromide 18 µg 
inhaler was added to their treatment regimen for 12 weeks and they were 
evaluated with spirometry every four weeks.  The patients were then categorized 
as responders or non-responders to tiotropium based on a finding of • 15% 
improvement in FEV1 for at least 8 consecutive weeks.  Of the 160 patients, 138  
(86%) enrollees completed the study.  Reasons for drop-out were five 
exacerbations, 11 patients noncompliant with treatment, and withdrawal of six 
patients from enrollment.  Out of the 138 patients that completed the study, 46 
(33.3%) were categorized as responders to tiotropium.  Of the remaining 
nonresponders, 15 had improvements in FEV1 • 15 but did not maintain that 
improvement for the full 8 week period.  The authors of this study concluded that 
tiotropium provided benefit to 33% of severe asthmatic patients with decreased 
lung function on standard therapy. 
The next article reviewed was authored by Kapoor et al. (2009) and is a 
case report on a 43-year old man with severe asthma requiring 20mg of oral 
prednisone, 500µg inhaled fluticasone and 50mg salmeterol as the Advair discus 
formulation, montelukast 10 mg daily and salbutemol rescue inhaler used several 
times a week.  His initial pulmonary function tests demonstrated his severe 
airflow restriction that was reversible with salbutemol.  Tiotropium 18µg daily was 
added to his treatment regimen for one year.  Initially, he had a PEF of 450L per 
minute.  After 3 months on tiotropium his oral prednisone was decreased to 
15mg daily and he had a PEF of 490L per minute.  Between 6 months and a year 
the patient’s oral prednisone dose was decreased to 2mg daily and he was able 
to maintain a PEF between 520 - 740L per minute.  The patient also reported 
improvements in his quality of life and exercise capacity.  The conclusion of this 
case report was that tiotropium may provide patients a “steroid sparing” benefit 
on high doses of oral glucocorticosteroids.  
The final study reviewed was conducted by Fardon, Haggart, Lee and 
Lipworth (2007) and was a randomized, double blind, placebo controlled, 
crossover study evaluating the benefit of halving the dose of ICS and adding 
either salmeterol and placebo or salmeterol and tiotropium.  Patients were 
included in the trial if they were over 18 years of age, with no history of an upper 
respiratory tract infection or use of oral corticosteroids in the past 3 months and 
they had an FEV1 • 65% and FVC of less than 80% of the predictive values for 
both respectively.  26 patients were enrolled in the trial.  The patients stopped all 
first and second line asthma treatments and were treated with 1000 µg 
fluticasone inhaler dosed as 250 µg two puffs twice daily for a four week run-in 
period.  The patients were then reevaluated using FEV1 and forced vital capacity 
(FVC) measurements as a baseline after the run-in period.  They were then 
randomly assigned to receive a total of 500 µg fluticasone and 100 µg salmeterol 
(125 µg fluticasone and 25 µg salmeterol 2 puffs twice daily) daily plus placebo 
tiotropium or the 500/100 dosing plus 18 µg tiotropium bromide inhaler.  Each 
study arm was treated for 4 weeks with cross-over after 4 weeks of treatment.  
The improvements from baseline (1000µg fluticasone) as measured by morning 
PEF were 41.6L per minute, 95% CI (14.4-68.6), p-value < 0.01 and 55.3l per 
minute, 95% CI (31.97-78.7), p-value < 0.01 for the fluticasone, salmeterol, 
placebo (F,S,P) group and the fluticasone, salmeterol and tiotropium (F,S,T) 
group respectively.  The change from baseline for the evening PEF was 37L per 
minute, 95% CI (12-63), p-value < 0.01 for the F,S,P group and 44L per minute, 
95% CI (26-62), p-value <0.01 for the F,S,T group.  The authors concluded that 
the addition of salmeterol and tiotropium to half the dose of fluticasone provided 
patients with a small amount of improvement in lung function compared with 
twice the dose of fluticasone. 
DISCUSSION 
All four articles included in this review reported significant improvements in 
pulmonary function with the use of tiotropium in those with moderate to severe 
asthma.  The articles by Peters et al. (2010) and Fardon et al, (2006) 
demonstrated the improvement in both PEF and FEV1.  The study conducted by 
Park et al. (2010) only reported the improvement in FEV1.  The case report by 
Kapoor et al. (2009) evaluated the improvements in lung function by PEF. 
The improvements noted in PEF and FEV1 by Fardon et al. (2006) were 
small but still statistically significant.  A limitation of their study is the small study 
population of 26 patients with only 18 (69%) completing the study.  An additional 
limitation to this crossover study was that there was no apparent wash out period 
between study arms.  The measurements of PEF and FEV1 were conducted 
during the study visits before and after the crossover with no wash-out period to 
return to the baseline line comparator of double-dose fluticasone.  Each segment 
of the trial was only four weeks in length.  This may have had an effect on the 
results of the crossover.  The patients in the first half of the study were stepped 
down to half the dose of fluticasone.  At the time of the crossover, the patients 
had already been on half the dose of fluticasone for four weeks.  Additionally, in 
the article by Park et al. (2010), they determined in a preliminary study that a 
treatment of eight weeks was necessary to note improvements in the FEV1 with 
tiotropium.  The short treatment length of each arm could lead to an 
underestimation of the true effect of tiotropium on lung function. 
The study by Peters et al. (2010) demonstrated a significant improvement 
in both morning PEF and FEV1 in patients that were given tiotropium in addition 
to an ICS.  This was compared to doubling the dose of the ICS.  They also found 
that the addition of tioptropium to an ICS was not inferior to the use of an ICS 
and salmeterol.  This study provided a longer treatment arm of 14 weeks and a 
four-week washout period between crossovers.  The potential limitations of this 
study include the moderate sized population of 210 patients and the reported 
compliance with treatment.  As part of the study oversight, treatment compliance 
was monitored.  Compliance percentages were reported as “84.1%±16.2%, 
92.6%±12.3%, and 93.0%±12.2%”  (p.1719) for beclamethasone, salmeterol and 
tiotropium, respectively.  The difference in treatment compliance between 
beclamethasone and salmeterol or tiotropium may have an effect on the 
pulmonary function measurements in this study. 
The article by Park, et al. (2009) demonstrates the response that severe 
asthmatic patients have with the addition of tiotropium.  Responders to tiotropium 
did have significant improvements in their FEV1 showing an improvement in one 
measure of their lung function.  However, there are several limitations to this 
article.  The primary weakness of this study is that it was an observational study 
with no comparator group.  Nor did the authors mention the time of day that the 
pulmonary function testing was completed.  This is significant since patients with 
asthma may have considerable differences in their FEV1 depending on the time 
of day.  It is not disclosed in the paper whether the patients were given the doses 
of tiotropium in the morning or the evening.  Without this information it is difficult 
to evaluate the true effect of tiotropium on lung function.  Timing of medication 
dosing can add several confounders to the analysis.  Patients can have a lower 
pre-dose trough FEV1 than a post-dose FEV1.  The time of day is also important 
in asthmatic patients with significant atopy.  The authors noted that the 
responders to tiotropium had higher rates of atopy determined by skin prick.  This 
can effect the lung function results based on exposure to potential allergens.  An 
additional limitation to the results is that only 86% of the patients completed the 
study.  Patients were dropped from the study due to exacerbations of their 
asthma, noncompliance or because they withdrew from enrollment.  This can 
provide a significant variation in the data in a study with 138 patients at the 
beginning of enrollment. 
According to the guidelines, oral corticosteroids should be considered in 
patients who are still unable to control their asthma symptoms despite the use of 
a high dose ICS and LABA.  The case report by Kapoor et al. (2010) 
demonstrates the benefit to lung function that tiotropium conferred on a patient 
still symptomatic despite using a high dose ICS, LABA, leukotriene modifier and 
oral corticosteroids.  Over a one-year period the patient had significant 
improvements in his PEF while slowly reducing his oral steroid dose from 20mg 
prednisone to 2mg daily.  This article has many limitations however.  First, it is a 
case report which means that the information is anecdotal instead of statistically 
relevant.  This patient also had a 15 pack-year smoking history.  This is a 
significant confounder because the worsening of symptoms since his first 
diagnosis at age 26 could be partially due to a COPD component of his airway 
disease.  The authors did note that the patient maintained some fixed airflow 
obstruction after bronchodilator use when measuring his initial FEV1. 
The evidence supporting the improvements in pulmonary function with 
tiotropium as an adjunct therapy to inhaled corticosteroids for adult patients with 
asthma we be evaluated using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach.  (Guyatt et al. 2008).  The 
GRADE approach was developed to evaluate the quality of clinical evidence in 
regards to patient management.  Levels of evidence include very low, low, 
moderate, and high.  The GRADE working group defines these levels of 
evidence as: 
High Quality – Further research is very unlikely to change our confidence 
in the estimate of effect 
Moderate quality – Further research is likely to have an important impact 
on the confidence in the estimate of effect and may change the estimate 
Low quality – Further research is very likely to have an important impact 
on our confidence in the estimate of effect and is likely to change the 
estimates 
Very low quality – Any estimate of effect is very uncertain (Guyatt et al. 
2008, p. 926) 
The outcomes evaluated in this review are the improvement in lung 
function, improvement in PEF and improvement in FEV1.  The evidence for these 
outcomes is listed in the GRADE table in the appendix. 
The two randomized clinical trials provided a moderate level of evidence 
to support the use of tiotropium to improve pulmonary function, PEF and FEV1.   
Their GRADE begins as a high level of evidence because they are RCTs.    Both 
studies did provide consistent evidence that tiotropium did improve pulmonary 
function, PEF and FEV1.  The overall evidence that they provide is decreased 
however because they are indirect comparisons of tiotropium.  Peters et al. 
(2010) and Fardon et al. (2006) had different treatment arms in their clinical trials 
and cannot be directly compared.  Overall, the two RCTs provided a moderate 
level of evidence. 
The case report article by Kapoor et al. (2010) demonstrated the 
improvements in pulmonary function and PEF.  This level of evidence begins as 
low quality due to it being a case report of a single patient.  It gains strength to a 
moderate level because of the significant dose response seen with the addition 
tiotropium as measured by the PEF and the decrease in use of oral glucosteroids 
OGS.  The authors were primarily reporting on the decrease in OGS versus the 
use of tiotropium with an ICS.  This causes this article to have the greatest 
indirectness with the other articles in terms of the authors outcomes but the 
improvements in PEF were directly related to the outcomes in this review. 
The study by Park et al. (2009) also showed in improvements in 
pulmonary function and FEV1 with the use of tiotropium.  Because it is an 
observational study the initial level of evidence is low.  The dose-response noted 
in this study increases its strength.  However, the obvious confounders 
mentioned above decrease the strength of the evidence.  This study provided a 
low quality of evidence for the outcomes evaluated in this review. 
The four articles reviewed here provide an overall moderate level of 
evidence of the improvement of pulmonary function, PEF and FEV1 seen with 
the use of tiotropium along with an ICS in the treatment of adults with asthma.   
Based on the GRADE assessment of the evidence, tiotropium appears to 
provide benefit to adult patients with asthma.  Further large-scale RCTs need to 
be conducted in order to recommend tiotropium be added to the asthma 
treatment guidelines.  Longer studies could adequately evaluate other outcomes 
such as decreases in exacerbations, decreases in rescue inhaler use, and 
improvements in quality of life.  Longer studies can also evaluate potential risks 
of long term use of tiotropium in asthma patients. 
In conclusion, the available data to date demonstrates that tiotropium in 
conjunction with an ICS provides statistically improved lung function in patients 
with moderate to severe asthma.  Tiotropium should be considered as a 
treatment option when patients are not well controlled on the currently 
recommended treatment regimens. 
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